Twitter Linkedin Youtube Campus Rubió
Methylphenidate hydrochloride

Rubifen Retard®

Home / Products / Rubifen Retard®
THERAPEUTIC INDICATION PRESENTATIONS

THERAPEUTIC INDICATION

 
Rubifen Retard® is indicated as part of a comprehensive treatment program for attention deficit/hyperactivity disorder (ADHD) in children from 6 years of age and adults when other measures have been shown to be insufficient on their own.

Treatment should be initiated and supervised by a specialist in child behavior disorders, a child and adolescent psychiatrist, or a psychiatrist.

     

  • Special diagnostic considerations for ADHD in children.

Diagnosis should be made according to DMS criteria or ICD guidelines and should be based on a complete history and evaluation of the patient. The diagnosis cannot be made solely on the presence of one or more symptoms.

The specific etiology of this syndrome is unknown, and there is no single diagnostic test. For an adequate diagnosis it is necessary to resort to clinical and specialized psychology, and to social and educational resources.

A comprehensive treatment program generally includes psychological, educational, and social measures as well as pharmacotherapy and is intended to stabilize children suffering from a behavioral syndrome characterized by symptoms that may include a chronic history of difficulty paying attention, being easily distracted, emotional instability, impulsiveness, moderate to severe hyperactivity, minor neurological signs, and abnormal electroencephalogram (EEG). Learning ability may or may not be impaired.

Treatment with Rubifen Retard® is not indicated for all children with ADHD and the decision to use the drug must be based on a very complete evaluation of the severity and chronicity of the child’s symptoms in relation to her age.

An appropriate educational placement is essential, and psychosocial intervention is often necessary. Where other measures have proven insufficient on their own, the decision to prescribe a stimulant should be based on a rigorous assessment of the severity of the child’s symptoms. The use of Rubifen Retard® must always be done in this way according to the authorized indication and the prescription and diagnostic guidelines.

     

  • Special diagnostic considerations for ADHD in adults

Diagnosis should be made according to DMS criteria or ICD guidelines and should be based on a complete history and evaluation of the patient.

The specific etiology of this syndrome is unknown, and there is no single diagnostic test.

Adults with ADHD exhibit symptom patterns characterized by restlessness, impatience, and absent-mindedness. Symptoms such as hyperactivity tend to decrease with increasing age, possibly due to adaptation, neurological development, and self-medication. Symptoms of inattention become more apparent and affect adults with ADHD to a greater extent. Diagnosis in adults should include a structured patient interview to determine current symptoms. The existence of ADHD in childhood is a requirement and must be determined retrospectively (by patient histories or, if these are not available, by appropriate and structured interviews). It is convenient to have the corroboration of a third person, and Rubifen Retard should not be started when verification of symptoms of ADHD in childhood is uncertain. The diagnosis cannot be made solely on the presence of one or more symptoms. The decision to use a stimulant in adults should be based on a rigorous evaluation, and the diagnosis should include moderate or severe functional impairment in at least 2 domains (eg, social, academic, and/or occupational activity), affecting several aspects of the individual’s life.

 
 

Download sheet

PRESENTATIONS

HDPE bottles with child-resistant (PP) safety closure. It is marketed in:

  • Rubifen Retard 10 mg 30 modified-release capsules, hard
  • Rubifen Retard 20 mg 30 modified-release capsules, hard
  • Rubifen Retard 30 mg 30 modified-release capsules, hard
  • Rubifen Retard 40 mg 30 modified-release capsules, hard

 

Scroll up
We want everyone to have access to our medicines wherever they are, regardless of prevalence.
OUR PRODUCTS
Las cookies son importantes para usted, influyen en su experiencia de navegación, nos ayudan a proteger su privacidad y permiten realizar las peticiones que nos solicite a través de la web. Utilizamos cookies propias y de terceros para analizar nuestros servicios y mostrarle publicidad relacionada con sus preferencias en base a un perfil elaborado con sus hábitos de navegación (por ejemplo, páginas visitadas). Si consiente su instalación pulse "Aceptar cookies", o también puede configurar sus preferencias pulsando "Configurar cookies". Más información en nuestra " Política de cookies"
Configurar cookies Aceptar cookies
Panel de configuración de cookies

Este es el configurador avanzado de cookies propias y de terceros. Aquí puede modificar parámetros que afectarán directamente a su experiencia de navegación en esta web.

Cookies Técnicas (necesarias)

Estas cookies son importantes para darte acceso seguro a zonas con información personal o para reconocerte cuando inicias sesión. Consultar Listado de Cookies Técnicas

Cookies de Personalización

Estas cookies están relacionadas con características generales como, por ejemplo, el navegador que utiliza, y podrá disponer de una experiencia y contenidos personalizados.Consultar Listado de Cookies de Personalización

No quiero cookies de Personalización (Con su selección no podemos ofrecerle una navegación y contenidos personalizados)
Cookies Analíticas

Permiten medir, de forma anónima, el número de visitas o la actividad. Gracias a ellas podemos mejorar constantemente su experiencia de navegación. Podrá disponer de una mejora continua en la experiencia de navegación.Consultar Listado de Cookies Analíticas

No quiero cookies Analíticas (Con su selección no podemos ofrecerle una mejora continua en la experiencia de navegación)
Guardar configuración